Intracavitary Therapeutics for Pleural Malignancies

Vivek Murthy, Keshav Mangalick, Daniel H. Sterman

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Pleural malignancies remain a serious therapeutic challenge, and are frequently refractory to standard treatment; however, they have the advantage of occurring in an enclosed cavity readily accessible for examination, biopsy, and serial sampling. Novel therapeutics can be administered via intracavitary delivery to maximize efficacy by targeting the site of involvement and potentially mitigating the adverse effects of systemic therapies. The easy accessibility of the pleural space lends itself well to repeated sampling and analysis to determine efficacy and toxicity of a given treatment paradigm. These factors support the rationale for delivery of novel therapeutics directly into the pleural space.

Original languageEnglish (US)
Pages (from-to)195-209
Number of pages15
JournalClinics in Chest Medicine
Volume39
Issue number1
DOIs
StatePublished - Mar 2018
Externally publishedYes

Fingerprint

Neoplasms
Therapeutics
Biopsy

Keywords

  • Intracavity therapeutics
  • Mesothelioma
  • Pleural malignancies
  • Pleural space

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Intracavitary Therapeutics for Pleural Malignancies. / Murthy, Vivek; Mangalick, Keshav; Sterman, Daniel H.

In: Clinics in Chest Medicine, Vol. 39, No. 1, 03.2018, p. 195-209.

Research output: Contribution to journalReview article

Murthy, Vivek ; Mangalick, Keshav ; Sterman, Daniel H. / Intracavitary Therapeutics for Pleural Malignancies. In: Clinics in Chest Medicine. 2018 ; Vol. 39, No. 1. pp. 195-209.
@article{2cde98719c0b46fdb8fbf65b3b88a60f,
title = "Intracavitary Therapeutics for Pleural Malignancies",
abstract = "Pleural malignancies remain a serious therapeutic challenge, and are frequently refractory to standard treatment; however, they have the advantage of occurring in an enclosed cavity readily accessible for examination, biopsy, and serial sampling. Novel therapeutics can be administered via intracavitary delivery to maximize efficacy by targeting the site of involvement and potentially mitigating the adverse effects of systemic therapies. The easy accessibility of the pleural space lends itself well to repeated sampling and analysis to determine efficacy and toxicity of a given treatment paradigm. These factors support the rationale for delivery of novel therapeutics directly into the pleural space.",
keywords = "Intracavity therapeutics, Mesothelioma, Pleural malignancies, Pleural space",
author = "Vivek Murthy and Keshav Mangalick and Sterman, {Daniel H.}",
year = "2018",
month = "3",
doi = "10.1016/j.ccm.2017.11.003",
language = "English (US)",
volume = "39",
pages = "195--209",
journal = "Clinics in Chest Medicine",
issn = "0272-5231",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Intracavitary Therapeutics for Pleural Malignancies

AU - Murthy, Vivek

AU - Mangalick, Keshav

AU - Sterman, Daniel H.

PY - 2018/3

Y1 - 2018/3

N2 - Pleural malignancies remain a serious therapeutic challenge, and are frequently refractory to standard treatment; however, they have the advantage of occurring in an enclosed cavity readily accessible for examination, biopsy, and serial sampling. Novel therapeutics can be administered via intracavitary delivery to maximize efficacy by targeting the site of involvement and potentially mitigating the adverse effects of systemic therapies. The easy accessibility of the pleural space lends itself well to repeated sampling and analysis to determine efficacy and toxicity of a given treatment paradigm. These factors support the rationale for delivery of novel therapeutics directly into the pleural space.

AB - Pleural malignancies remain a serious therapeutic challenge, and are frequently refractory to standard treatment; however, they have the advantage of occurring in an enclosed cavity readily accessible for examination, biopsy, and serial sampling. Novel therapeutics can be administered via intracavitary delivery to maximize efficacy by targeting the site of involvement and potentially mitigating the adverse effects of systemic therapies. The easy accessibility of the pleural space lends itself well to repeated sampling and analysis to determine efficacy and toxicity of a given treatment paradigm. These factors support the rationale for delivery of novel therapeutics directly into the pleural space.

KW - Intracavity therapeutics

KW - Mesothelioma

KW - Pleural malignancies

KW - Pleural space

UR - http://www.scopus.com/inward/record.url?scp=85039043785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039043785&partnerID=8YFLogxK

U2 - 10.1016/j.ccm.2017.11.003

DO - 10.1016/j.ccm.2017.11.003

M3 - Review article

C2 - 29433715

AN - SCOPUS:85039043785

VL - 39

SP - 195

EP - 209

JO - Clinics in Chest Medicine

JF - Clinics in Chest Medicine

SN - 0272-5231

IS - 1

ER -